posted on 2012-10-02, 00:00authored byBruno Sainz Jr, Naina Barretto, Xuemei Yu, Peter Corcoran, Susan L Uprichard
Background: Although primary and established human hepatoma cell lines have been evaluated for hepatitis C
virus (HCV) infection in vitro, thus far only Huh7 cells have been found to be highly permissive for infectious HCV.
Since our understanding of the HCV lifecycle would benefit from the identification of additional permissive cell
lines, we assembled a panel of hepatic and non-hepatic cell lines and assessed their ability to support HCV
infection. Here we show infection of the human hepatoma cell lines PLC/PRF/5 and Hep3B with cell culturederived
HCV (HCVcc), albeit to lower levels than that achieved in Huh7 cells. To better understand the reduced
permissiveness of PLC and Hep3B cells for HCVcc infection, we performed studies to evaluate the ability of each
cell line to support specific steps of the viral lifecycle (i.e. entry, replication, egress and spread).
Results: We found that while the early events in HCV infection (i.e. entry plus replication initiation) are
cumulatively equivalent or only marginally reduced in PLC and Hep3B cells, later steps of the viral life cycle such as
steady-state replication, de novo virus production and/or spread are impaired to different degrees in PLC and
Hep3B cultures compared to Huh7 cell cultures. Interestingly, we also observed that interferon stimulated gene (i.e.
ISG56) expression was significantly and differentially up-regulated in PLC and Hep3B cells following viral infection.
Conclusions: We conclude that the restrictions observed later during HCV infection in these cell lines could in part
be attributed to HCV-induced innate signaling. Nevertheless, the identification of two new cell lines capable of
supporting authentic HCVcc infection, even at reduced levels, expands the current repertoire of cell lines
amendable for the study of HCV in vitro and should aid in further elucidating HCV biology and the cellular
determinants that modulate HCV infection.
Funding
This work was supported by the National Institutes of Health Public Health
Service Grants R56/R01-AI078881 and R21-CA133266 and the University of
Illinois Chicago Council to support Gastrointestinal and Liver Disease